c-erB-2 oncoprotein expression in malignant and nonmalignant breast tissue

Area of Science:

• Oncology
• Molecular Biology
• Immunohistochemistry

Background:

• The c-erbB-2 oncoprotein is a transmembrane receptor implicated in cancer development.
• Accurate detection of c-erbB-2 overexpression is crucial for breast cancer diagnosis and treatment.

Purpose of the Study:

• To evaluate the utility of a specific polyclonal antibody (21N) for immunohistochemical detection of c-erbB-2 oncoprotein.
• To determine the prevalence of c-erbB-2 overexpression in primary breast carcinomas and benign breast lesions.

Main Methods:

• Immunohistochemical staining of 200 primary breast carcinomas and 46 benign breast lesions using the 21N antibody.
• Analysis of staining patterns, predominantly at the cell membrane, indicative of c-erbB-2 overexpression.

Main Results:

• C-erbB-2 overexpression was identified in 17% (34/200) of primary breast carcinomas.
• No significant c-erbB-2 positivity was observed in benign breast samples, except for one case of apocrine metaplasia.
• Immunohistochemistry on paraffin-embedded sections proved effective for detecting c-erbB-2 overexpression.

Conclusions:

• Immunohistochemical detection of c-erbB-2 oncoprotein is feasible and reliable using the 21N antibody.
• Overexpression of c-erbB-2 is a marker predominantly associated with the malignant phenotype in breast tissue.
• These findings support the use of immunohistochemistry for identifying c-erbB-2 overexpression in breast cancer.